Abzena Share Discussion Threads

[babbler] 20/1/2017 16:42

Actually look at chart it rose. A little.

[escapetohome] 20/1/2017 16:22

Disappointed towards the end share price dropped off

[qs99] 20/1/2017 16:20

not sure why there would be millie, but that is IMO....broker notes I see don't suggest that...but DYOR...

[babbler] 20/1/2017 16:20

£9m cash Sept last year. So possibly but that's quite a lot of cash.

[milliecusto] 20/1/2017 15:32

is there a fund raiser possible in the short term

[gimmetheloot] 20/1/2017 14:39

US market waking up to the news. Just watch this afternoon.

Glenbo I'm being conservative when I say between £1.25 - £1.75.

This is a deal and a half. Market cap should be 5 x earnings!! Work it out on 300 million revenues??

[glenbo1] 20/1/2017 14:03

What is a realistic mcap here short and medium term?

[qs99] 20/1/2017 13:12

Hopefully get picked up by usual culprits next week that should help drive this further IMO, albeit only back to its IPO pricing at least IMO! gla

[qs99] 20/1/2017 11:56

Yup looks like decent potential here, hopefully this year will see more such deals which is what it is all about IMO.

Gla and DYOR, just the beginning IMO

[mr hat] 20/1/2017 10:41

The Group has a global customer base which includes the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.

[gimmetheloot] 20/1/2017 10:25

This was 80p in May!!

[gimmetheloot] 20/1/2017 10:24

1.3 billion market cap potential within the short term or 12-18 months!! 80 million market cap 15 bagged from her buy and hold that's it!!

[gimmetheloot] 20/1/2017 10:14

Over 300 million

[gimmetheloot] 20/1/2017 10:13

The value of the agreement to Abzena has the potential to reach over $300 million, comprising licence fees and milestone payments. In addition, Abzena would also receive royalties on sales of approved products that incorporate the ThioBridge(TM) technology developed by its partner.

Dr John Burt, CEO of Abzena, commented:

"Abzena and the US biopharmaceutical company has enjoyed an ongoing collaborative research programme to evaluate ThioBridge(TM) up until now. The collaboration has allowed both parties to build a strong working relationship and to demonstrate the value of the ThioBridge(TM) technology in creating novel ADCs.

"Signing this extensive licence agreement for ThioBridge(TM) is further validation of our proprietary ADC technology and expertise. We look forward to continuing to work together with our partner for the development of novel ThioBridge(TM)

[qs99] 20/1/2017 08:43

yup, prefer this thread, couldn't get the charts to work on mine so ignore that one, apologies. Well done all that are on board! Brokers have 93-£1 target price or intrinsic value price DYOR but IMO the outlook statement from them suggest more to come following further progression on licencing deals etc etc. Very tightly held, but positive news will see this further. GLA and am holding on...

[arab3] 20/1/2017 08:33

when did you buy in keya ?

[keya5000] 20/1/2017 08:30

Well jog on then.......

[22richyrich] 20/1/2017 07:41

On initial read of rns sounds positive $300million potential income..but then looked at share price last 12 months and fact this deal at lower value was announced 10 months ago and realised it's a classic loss making aim jam tomorrow story

[escapetohome] 22/12/2016 07:54

License agreement, a step forward?

[escapetohome] 24/10/2016 19:43

These new appointments need to get cracking and buy some shares.

[aim_trader] 30/9/2016 10:27

Abzena CEO John Burt will be presenting at the Biotech Capital Conference in London on the 4th October. For further details and to register to attend, please click here: